Literature DB >> 17469686

Assessment of behavioural and psychological symptoms associated with dementia.

David Conn1, Lilian Thorpe.   

Abstract

Neuropsychiatric symptoms (mood, psychotic, and behavioural) are very common in dementia and do not necessarily correlate well with other measures of cognition. However, these symptoms are of great importance, as they are a major source of excess disability, patient distress and caregiver burden and have great impact on the level of care required, and the associated costs. This paper is a review of the most useful outcome measures for behaviour and mood symptoms. Investigators who require a comprehensive instrument to measure neuropsychiatric symptoms in studies of patients with dementia should consider using the Neuropsychiatric Inventory (NPI), the Behavior Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD-BRSD) or, possibly, the Behavioral Pathology in Alzheimer's Disease Scale (BEHAVE-AD). The Cornell Scale for Depression in Dementia and the Dementia Mood Assessment Scale (DMAS) are recommended for evaluating depressive symptoms and the Cohen-Mansfield Agitation Inventory (CMAI) is very useful for evaluating the full range of agitation symptoms.

Entities:  

Mesh:

Year:  2007        PMID: 17469686     DOI: 10.1017/s0317167100005606

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  9 in total

1.  Alzheimer's therapies.

Authors:  Elisa F Cascade; Amir H Kalali; Edmund Howe
Journal:  Psychiatry (Edgmont)       Date:  2007-08

2.  Treatments for Depression in Older Persons with Dementia.

Authors:  Zvi D Gellis; Kimberly P McClive-Reed; Ellen Brown
Journal:  Ann Longterm Care       Date:  2009-02-02

3.  Dietary supplementation with S-adenosyl methionine was associated with protracted reduction of seizures in a line of transgenic mice.

Authors:  Sheryl Perry; James Levasseur; Amy Chan; Thomas B Shea
Journal:  Comp Med       Date:  2008-12       Impact factor: 0.982

Review 4.  Assessing neuropsychiatric symptoms in people with dementia: a systematic review of measures.

Authors:  Laura N Gitlin; Katherine A Marx; Ian H Stanley; Bryan R Hansen; Kimberly S Van Haitsma
Journal:  Int Psychogeriatr       Date:  2014-08-06       Impact factor: 3.878

5.  The implementation of the serial trial intervention for pain and challenging behaviour in advanced dementia patients (STA OP!): a clustered randomized controlled trial.

Authors:  Marjoleine J C Pieper; Wilco P Achterberg; Anneke L Francke; Jenny T van der Steen; Erik J A Scherder; Christine R Kovach
Journal:  BMC Geriatr       Date:  2011-03-24       Impact factor: 3.921

6.  Potential Antidepressant Role of Neurotransmitter CART: Implications for Mental Disorders.

Authors:  Peizhong Mao
Journal:  Depress Res Treat       Date:  2011-07-07

Review 7.  The Hyperactivity-Impulsivity-Irritiability-Disinhibition-Aggression-Agitation Domain in Alzheimer's Disease: Current Management and Future Directions.

Authors:  Rachel M Keszycki; Daniel W Fisher; Hongxin Dong
Journal:  Front Pharmacol       Date:  2019-09-27       Impact factor: 5.810

8.  Effects of COVID-19 Pandemic Confinement in Patients With Cognitive Impairment.

Authors:  Ainara Barguilla; Aida Fernández-Lebrero; Isabel Estragués-Gázquez; Greta García-Escobar; Irene Navalpotro-Gómez; Rosa María Manero; Víctor Puente-Periz; Jaume Roquer; Albert Puig-Pijoan
Journal:  Front Neurol       Date:  2020-11-24       Impact factor: 4.003

Review 9.  The merits and problems of Neuropsychiatric Inventory as an assessment tool in people with dementia and other neurological disorders.

Authors:  Claudia K Y Lai
Journal:  Clin Interv Aging       Date:  2014-07-08       Impact factor: 4.458

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.